Formulation Development:
VerGo Pharma Research offers comprehensive formulation development services for oral solid dosage forms (OSD), including, oral liquids, supporting both potent (OEB 3) and non-potent molecules. Our dedicated R&D infrastructure enables efficient scale-up from feasibility to pilot BE batches.
Capabilities include:
- OSD Expertise: Tablets (bi-layered, MUPS, ODTs, sublingual, effervescent), hard-gelatin capsules (powder, granules, pellets) and FDCs.
- Modified Release Forms: Sustained Release (SR), Delayed Release (DR), and Modified Release (MR) formulations.
- Oral Liquids: Solutions, suspensions and emulsions.
- Powders & Powder for Oral Suspension (PFOS): Bottles and sachet packs.
- Special Product Development: Dedicated lab for formulation development of cytotoxic, steroidal and immuno-suppressant drugs (up to OEB 3).
- Pilot BE Batches: Capability to manufacture pilot batches for bioequivalence studies.
- Patent Strategies: Proven track record in non-infringing and FTF approaches, including experience with NCE-1 products.
- Complex / Hybrid Formulations
- Feasibility & proof of concept studies
Analytical Development
Our analytical development division ensures robust characterization and validation of pharmaceutical products through advanced instrumentation and scientific precision.
Capabilities include:
- Method Development & Validation: Comprehensive method development, validation and transfer.
- Structural Elucidation: Impurity isolation and characterization using advanced analytical
techniques. - Pre-formulation Studies: Physicochemical profiling and compatibility assessments.
- Dissolution Testing: USP Type I, II and III apparatus for dissolution profiling.
- Instrumentation: Equipped with GC, HPLC, UPLC and DSC.
- Cytotoxic Testing Lab: Dedicated analytical facility for cytotoxic products (up to OEB 3).
VerGo Pharma drives innovation through integrated formulation and analytical development capabilities that transform concepts into compliant, market-ready products. With a focus on oral solid dosage forms (OSD) and expertise with complex generics and differentiated formulations, our R&D teams combine scientific precision with strategic foresight – enabling partners to accelerate development timelines, optimize product performance and achieve regulatory success across global markets.
Our approach blends technical depth with business agility, ensuring every formulation and analytical solution supports commercial scalability, regulatory & patent strategy and long-term market differentiation value.